Do We Need To Reset The Rules Of Oncology? with Dr. Johnetta Blakely - ADAPTIVE BIOTECHNOLOGIES CORP

Financial Performance:

• No specific financial metrics (revenue, earnings, margins, cash flow, debt) for the hosting company were disclosed in this earnings call transcript.
• Discussion highlights that independent community oncology practices face significant economic pressure, with overhead costs (workforce, rent, electricity) rising, forcing consolidation into hospital systems to survive.
• Dr. Blakely notes that community practices remain 33% less expensive than hospital-based clinics for infusions, offering savings to patients and insurers while maintaining quality care.

Guidance and Future Outlook:

• Outlook for AI adoption in healthcare is positive, with a trajectory toward deeper integration to reduce administrative burdens and personalize care, though current technology is described as being in an "infant stage."
• Future growth for community oncology depends on maintaining independence through partnerships (e.g., with MSOs like One Oncology) to achieve economies of scale in benefits, IT, and drug purchasing.
• Long-term goal involves closing the "implementation gap" where innovative therapies (like CAR-T) take years to reach community practices; the target is to accelerate the transition from clinical trials to standard community care.
• Policy outlook includes anticipated legislative fixes for the Inflation Reduction Act (IRA) to prevent damage to small practices and the protection of R&D incentives for rare disease indications.

Business Segments and Product Lines:

• DeepScribe/AI: Successfully integrated ambient AI note-taking tools; Dr. Blakely reports an 80% adoption rate within her specific group, significantly reducing after-hours note writing and preventing work from being brought home.
• CAR-T and Bispecifics: Community practices are beginning to adopt these curative but complex therapies; Tennessee Oncology recently passed FACT accreditation reviews to enable this, though a "chicken and egg" barrier exists (insurers require accreditation, but accreditation requires prior experience).
• Telemedicine & Data Centers: Telemedicine adoption accelerated by the pandemic is expected to evolve alongside the infrastructure needs of AI, including the development of eco-friendly data centers that provide local tax revenue and grid support.

Market and Competitive Landscape:

• Market Share Trends: The proportion of independent community oncology practices has dropped from ~69% five years ago to ~37% due to hospital consolidation driven by economic pressures.
• Access Disparity: Only 20% (2 out of 10) of patients eligible for curative CAR-T therapy currently receive it, largely due to geographical barriers and lack of availability in rural/underserved communities.
• Academic vs. Community: While academic centers drive new drug discovery, the majority of cancer care volume is delivered in community settings; the ecosystem relies on the coexistence of both, with community practices filling gaps in rural access that hospitals avoid.

Risks and Challenges:

• Regulatory Burden: Excessive "box clicking" for compliance (e.g., repetitive smoking cessation queries) creates administrative friction and distracts from patient-centric care; current EMR systems are described as "clunky" and "albatrosses."
• IRA Unintended Consequences: Drug price negotiations (starting 2026 for oral drugs, 2028 for IV) could eliminate the 4.3% reimbursement margin community practices rely on for overhead, potentially threatening their viability.
• R&D Impact: Aggressive drug pricing may reduce the capital available for pharmaceutical companies to fund research into rare diseases and new indications (e.g., pediatric or sarcoma), risking a shift of innovation to countries with lower regulatory standards.
• Operational Barriers: The "chicken and egg" problem of CAR-T accreditation (insurers won't pay without FACT accreditation, but accreditation requires prior cases) delays patient access to life-saving treatments.

Management Commentary and Tone:

• Tone: The commentary is urgent, realistic, and empathetic toward physician burnout. Dr. Blakely expresses strong frustration with bureaucratic inefficiencies but remains hopeful about technology's ability to "re-interrogate" and reset old workflows.
• Confidence: High confidence in the value of AI and independent community practices; Dr. Blakely explicitly states she would not return to pre-AI workflows and views community oncology as essential for national health equity.
• Adoption Philosophy: Emphasizes that technology adoption requires physician champions and that "the best technology doesn't always win; the technology that bends to the end-user does."

Analyst Questions and Answers:

• Q: How to earn clinician trust in AI tools?
  • A: Acknowledge the "regimented" nature of physicians; use early adopters (guinea pigs) to prove value; ensure seamless EMR integration (e.g., Chrome extensions) rather than switching platforms; and allow for feedback loops where clinicians can customize outputs (e.g., spelling corrections, formatting).
• Q: Why is staying independent important for community practices?
  • A: Independence allows for faster decision-making, lower costs (33% savings on infusions), and the ability to serve rural areas hospitals ignore; it ensures access for patients regardless of geography.
• Q: What should technologists understand about doctors?
  • A: Doctors are highly regimented and resistant to workflow disruption; changes are not simple "plug-and-play" and often require significant coding effort; adoption relies on peer influence rather than vendor promises.

Other Key Points:

• 340B Program Critique: While originally intended for underserved clinics, the program has "drifted off the rails" with large hospitals (e.g., Beverly Hills) now participating, potentially diverting resources away from the intended underserved populations.
• Legal Protection: AI transcription tools provide a defensive layer against false malpractice claims or patient disputes, creating an objective record of interactions.
• Pandemic Legacy: The COVID-19 pandemic acted as a forcing function for healthcare technology adoption (telemedicine), and Dr. Blakely argues the industry should not wait for another crisis to implement AI-driven efficiencies.
• Data Ethics: Concerns about data privacy in AI are addressed by transparency with patients (e.g., announcing recording) and the inherent value of providing free, albeit imperfect, medical information access in underserved areas compared to misinformation or no information.